Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 91,200 shares, a growth of 12.9% from the July 15th total of 80,800 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average trading volume of 75,000 shares, the days-to-cover ratio is presently 1.2 days.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences as of its most recent filing with the SEC. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Stock Up 3.3 %

Aptose Biosciences stock traded up $0.02 during mid-day trading on Friday, hitting $0.50. 66,027 shares of the company’s stock were exchanged, compared to its average volume of 79,167. The company’s 50 day simple moving average is $0.67 and its 200-day simple moving average is $1.20. The firm has a market capitalization of $9.05 million, a P/E ratio of -0.08 and a beta of 1.27. Aptose Biosciences has a fifty-two week low of $0.40 and a fifty-two week high of $5.02.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15. Research analysts expect that Aptose Biosciences will post -2.62 EPS for the current year.

Analysts Set New Price Targets

APTO has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Aptose Biosciences in a research report on Friday, June 14th. StockNews.com initiated coverage on Aptose Biosciences in a research note on Saturday. They issued a “hold” rating on the stock. Finally, Canaccord Genuity Group decreased their target price on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Aptose Biosciences has a consensus rating of “Moderate Buy” and an average target price of $14.80.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.